Foundation Medicine introduces first pan-cancer genomic profile

Foundation Medicine announced today the commercial launch of FoundationOne™, the first pan-cancer, fully informative genomic profile designed to help oncologists expand their patients' treatment options. FoundationOne is optimized to fit current oncology practice. It uses clinical-grade, next-generation sequencing to interrogate hundreds of cancer-related genes from routine, formalin-fixed, paraffin-embedded tumor samples. Test results are provided in a straightforward report that aligns detected genomic alterations with potential treatment options and clinical trials.

"The launch of FoundationOne marks an important moment in the field of oncology," said Michael J. Pellini, M.D., Foundation Medicine's chief executive officer. "This first commercial product from Foundation Medicine is the result of a convergence of genomic sequencing, information technology and clinical practice that would not have been possible at any other point in history. Foundation Medicine is the first company with the ability to put these advances into everyday care, giving oncologists the molecular blueprint of each patient's cancer to help inform a more targeted treatment strategy."

FoundationOne interrogates all genes somatically altered in human solid tumors that are validated targets for therapy or drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations, including base substitutions, insertions, deletions, copy number alterations and select rearrangements. Genomic profile results are reported to the physician for each individual patient along with targeted therapies and clinical trials that may be relevant based on the specific alterations identified in the patient's tumor and the most recent scientific and medical evidence.

"FoundationOne brings a best-in-class molecular diagnostic to all oncologists and pathologists, both in the community where most patients are treated and at major academic centers," said Vincent Miller, M.D., senior vice president of clinical development, Foundation Medicine. "FoundationOne gives physicians a powerful new tool to help them incorporate the latest genomic findings into treatment decisions for each patient. The commercial availability of FoundationOne is perfectly timed to accelerate the clinical adoption of the burgeoning molecular information in oncology."

Early clinical studies with FoundationOne have demonstrated high accuracy and an ability to interrogate all classes of potentially actionable alterations to reveal clinically-relevant information. Since receiving CLIA certification in October, 2011 and beginning pre-launch operations, Foundation Medicine has shown that FoundationOne reveals, on average, approximately three reportable alterations per patient sample and three times as many actionable alterations than the most comprehensive "hot spot" panels or tests currently available. FoundationOne sequences hundreds of genes known to be clinically relevant in cancer and identifies any actionable alterations, whereas existing technologies are able to find only pre-determined alterations. Experience to-date shows that FoundationOne can identify previously undetectable, yet potentially actionable, alterations, and suggests that FoundationOne will profoundly increase the application of molecular information in clinical practice.

Source: Foundation Medicine

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Consumption of highly refined fiber may increase liver cancer risk in some people